Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Covid-19 and Spontaneous Pneumothorax: A Survival Analysis Publisher Pubmed



Ershadi R1 ; Rafieian S1 ; Salehi M2 ; Kazemizadeh H3 ; Amini H1 ; Sohrabi M4 ; Samimiat A5 ; Sharafi Y6 ; Dashtkoohi M7 ; Vahedi M5
Authors

Source: Journal of Cardiothoracic Surgery Published:2023


Abstract

Introduction: COVID-19 Patients may be at risk for involving with spontaneous pneumothorax. However, clinical data are lacking in this regard. In this study, we aimed to investigate the demographic, clinical, and radiological characteristics and survival predictors in COVID-19 patients with pneumothorax. Methods: This is a retrospectivestudy conducted on COVID-19 patients with pneumothorax that had been hospitalized at hospital. l from December 2021 to March 2022. The chest computed tomography (CT) scan of all patients was reviewed by an experienced pulmonologist in search of pulmonary pneumothorax. Survival analysis was conducted to identify the predictors of survival in patients with COVID-19 and pneumothorax. Results: A total of 67 patients with COVID-19 and pneumothorax were identified. Of these, 40.7% were located in the left lung, 40.7% were in the right lung, and 18.6% were found bilaterally. The most common symptoms in the patient with pneumothorax were dyspnea (65.7%), increased cough severity (53.7%), chest pain (25.4%), and hemoptysis (16.4%). The frequency of pulmonary left and right bullae, pleural effusion, andfungus ball were 22.4%, 22.4%, 22.4%, and 7.5%, respectively. Pneumothorax was managed with chest drain (80.6%), chest drain and surgery (6%), and conservatively (13.4%). The 50-day mortality rate was 52.2% (35 patients). The average survival time for deceased patients was 10.06 (2.17) days. Conclusions: Our results demonstrated that those with pleural effusion or pulmonary bullae have a lower survival rate. Further studies are required to investigate the incidence and causality relation between COVID-19 and pneumothorax. © 2023, The Author(s).
Other Related Docs
9. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
10. Clinical Manifestations of Covid-19, Advances in Experimental Medicine and Biology (2021)
11. Analyzing Trends in Demographic, Laboratory, Imaging, and Clinical Outcomes of Icu-Hospitalized Covid-19 Patients, Canadian Journal of Infectious Diseases and Medical Microbiology (2023)
15. Computed Tomography Findings in 3,557 Covid-19 Infected Children: A Systematic Review, Quantitative Imaging in Medicine and Surgery (2021)